

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/694,001
Filing Date	October 28, 2003
First Named Inventor	Bernward SCHÖLKENS
Art Unit	1614
Examiner Name	R. Henley, III
Attorney Docket Number	02481.1707-01

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
[Signature]		5,266,583	11/1993	Ohtawa	
		5,308,846	05/1994	Allen et al.	
		5,656,603	08/1997	Simmons	
		2005/0101658 A1	05/2005	Scholken et al.	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
[Signature]		GB 2 308 064	06/1997	[X]	[X]	
		DE 4308504	09/1994			
		DE 199 13 528 A1	06/2000			
		EP 0 241 201	10/1987			
		EP 0 540 209	05/1993			
		EP 0 747 050	12/1996			
		WO 97/27745	08/1997			
		WO 97/49392	12/1997			
		WO 98/30216	07/1998			
		WO 99/44590	09/1999			
		WO 00/02543	01/2000			
		WO 00/71751	11/2000			
		WO 01/15674	03/2001			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
[Signature]		English language Derwent Abstract of DE 4308504 <i>Year not available</i>	
		English language Derwent Abstract of DE 199 13 528 A1 <i>Year not available</i>	
		Copy of Office Action dated July 27, 2004, in application No. 09/645,556	
		Copy of Office Action dated November 3, 2004, in application No. 09/645,556	
		Copy of Office Action dated January 24, 2005, in application No. 09/645,556	
		Copy of Office Action dated February 24, 2005, in application No. 09/645,556	
		Copy of Office Action dated June 29, 2005, in application No. 09/645,556	
[Signature]		M.I. Balabolkin, "Endocrinology," Universum Publishing, pp. 390-391, 1998, with English language translation of portion of text	

Rd/H 14/24/05

DS Form PTO/SB/08: Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheets: 2 of 2

Complete if Known

Application Number	10/694,001
Filing Date	October 28, 2003
First Named Inventor	Bernward SCHÖLKENS
Art Unit	1614
Examiner Name	R. Henley, III
Attorney Docket Number	02481.1707-01

NON PATENT LITERATURE DOCUMENTS		
1		<p>Mei Blumenthal, Treatment of Congestive Heart Failure, Experience With Fosinopril, American Journal of Hypertension, Ltd. 1997, vol. 10, No. 10, Part 2, pgs. S289-S298</p> <p>Bussien et al., The effect of the converting enzyme inhibitor HOE-498 (ramipril) on the renin angiotensin system of normal volunteers. Naunyn-Schmiedeberg's Archives of Pharmacology, 1985, vol. 329, pages 63-69</p> <p>Cashin-Hemphill et al., "Angiotensin-Converting Enzyme Inhibition as Antiatherosclerotic Therapy: No Answer Yet," Am. J. Cardiol., vol. 83, pp. 43-47 (1999)</p> <p>Database WPI, Week 19944, Derwent Publications Ltd., London, GB, AN 199-520858, XP-002166044, Masuda Yoshinobu, Honda Yayoi, Minato Hisao: "Inhibitor of cerebral vasospasm" (Date not available)</p> <p>Robert T. Eberhardt et al., Angiotensin II Receptor Blockade: An Innovative Approach to Cardiovascular Pharmacotherapy, J. Clin. Pharmacol 1993, 33:1023-1038, XP-001019614</p> <p>FDA Orange Book Active Ingredient Detail Record Search, June 1998</p> <p>The GISEN Group, "Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy," THE LANCET, Vol. 349, 1997, pp. 1857-1863</p> <p>Alistair S. Hall et al., "Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study," THE LANCET, Vol. 349, 1997, pp. 1493-1497</p> <p>Willia A. Hsueh, MD, "In diabetes, treat hidden heart disease," Cleveland Clinic Journal of Medicine, vol. 67, no. 11, pages 807-813, November 2000</p> <p>Robert MKW Lee et al., Effects of perindopril on hypertension and stroke prevention in experimental animals, Can. J. Cardiol., vol. 10, no. Suppl. D, November 1994, pgs. 33D-36D, XP000998206</p> <p>V.I. Metelitsa, "Handbook on Clinical Pharmacology of Cardiovascular Medicaments," Medpraktika, 1996, pp. 619 and 272, with English language translation of portion of text</p> <p>Fumiaki Nakamura et al., Chronic Administration of Angiotensin II Receptor Antagonist, TCv-116, In Cardiomyopathic Hamsters, American Physiological Society, 1994, pgs. H2297-H2304, XP-001019610</p> <p>Noriko Ogiku et al., Prophylactic Effect of Imidapril on Stroke in Stroke-Prone Spontaneously Hypertensive Rats; Stroke, (Feb 1993) 24 (2) 245-52, XP000997781</p> <p>K. Parfitt, Martindale - The Complete Drug Reference - Thirty-second Edition, 1999, Pharmaceutical Press, London, U.K., XP-002176301, pp. 836, 865, 891, 899, 951 and 960</p> <p>J.E.F. Reynolds, "Martindale The Extra Pharmacopoeia, 1996, Royal Pharmaceutical Society, London, XP002166043, pp. 863, 864, 899, 900, 940 and 941</p> <p>Charles T. Stier, Jr., et al., Enalapril Prevents Stroke and Kidney Dysfunction in Salt-Loaded Stroke-Prone Spontaneously Hypertensive Rats; Hypertension (Dallas), vol. 13, no. 2, 1989, pgs. 115-121, XP000997775</p> <p>Charles T. Stier, Jr. et al., Stroke Prevention by Losartan in Stroke-prone Spontaneously Hypertensive Rats, Journal of Hypertension 1993, 11 (suppl 3) 537-542, XP-00109687</p> <p>P. Trenkwalder, "Effects of candesartan cilexetil on glucose homeostasis," Basic Res Cardiol, 93:Suppl. 2, pp. 140-144, 1998</p> <p>Webb et al., Vascular Angiotensin Conversion in Humans, Journal of Cardiovascular Pharmacology, 8 (Suppl. 10), S40-S44, 1986</p>

Examiner Signature:	Date Considered: 10/26/05
---------------------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.